We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Frank Scott

Frank I. Scott MD MSCE

Frank I. Scott, MD, MSCE, is an expert in inflammatory bowel disease and epidemiology at the Crohn’s and Colitis Center in the Division of Gastroenterology and Hepatology at the University of Colorado Anschutz Medical Campus. His research interests include maximizing the risk-benefit balance of biologic and immunosuppressive therapies in IBD, optimizing medication delivery in IBD, and exploring novel pharmacoepidemiologic association in IBD and other gastrointestinal disorders.  His work has been funded by the National Institutes of Health, Crohn’s and Colitis Foundation, and several industry partners.

Disclosures

Dr. Scott reports having received research grants from the National Institutes of Health, Crohn’s and Colitis Foundation, Takeda Pharmaceuticals USA , and Janssen Pharmaceuticals, and having received consulting fees from PRIME Incorporated, Janssen Pharmaceuticals, Takeda Pharmaceuticals, and Merck Pharmaceuticals.